Another day, another patent litigation settlement for Actavis (ACT +2.3%). The company says it has reached an agreement with Purdue Pharmaceuticals under which ACT will be licensed to sell "a specific number of bottles of generic OxyContin" beginning early next year assuming the company obtains FDA approval. The deal could potentially mean $100M in gross profits for ACT in 2014 and 2015. (PR)